Below is a text only representation of the Patient Information Leaflet, the original can be viewed in PDF format using the link above.
The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet are: EU/1/13/885/001, EU/1/13/885/002.
Kadcyla100 mg powder for concentrate for solution for infusion
Kadcyla 160 mg powder for concentrate for solution for infusion
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
1. What Kadcyla is and what it is used for
2. What you need to know before you are given Kadcyla
3. How you are given Kadcyla
4. Possible side effects
5. How to store Kadcyla
6. Contents of the pack and other information
Kadcyla contains the active substance trastuzumab emtansine, which is made up of two parts that are linked together:
- trastuzumab - a monoclonal antibody that binds selectively to an antigen (a target protein) called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When trastuzumab binds to HER2 it can stop the cancer cells growth and
cause them to die.
- DM1 – an anti-cancer substance that becomes active once Kadcyla enters the cancer cell.
Kadcyla is used to treat breast cancer in adults when:
- the cancer cells have many HER2 proteins on them - your doctor will test your cancer cells for this.
- you have already received the medicine trastuzumab and a medicine known as a taxane.
- the cancer has spread to areas near the breast or to other parts of your body
- if you are allergic to trastuzumab emtansine or any of the other ingredients of this medicine (listed in section 6).
You should not be given Kadcyla if the above applies to you. If you are not sure, talk to your doctor or nurse before you are given Kadcyla.
Talk to your doctor or nurse before you are given Kadcyla if:
- you have ever had a serious infusion-related reaction from using trastuzumab characterised by symptoms such as flushing, chills, fever, shortness of breath, difficulty breathing, rapid heartbeat or a drop in blood pressure.
- you are receiving treatment with blood thinning medicines (e.g. warfarin, heparin).
- you have any history of liver problems. Your doctor will check your blood to test your liver function before and regularly during treatment
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before you are given Kadcyla.
Kadcyla can make some existing conditions worse, or cause side effects. See section 4 for more details about what side effects to look out for.
- Breathing problems: Kadcyla can cause serious breathing problems such as shortness of breath (either at rest or while performing any type of activity)
and cough. These may be signs of inflammation of your lung, which may be serious, and even fatal. If you develop lung disease your doctor may stop treatment with this medicine.
- Liver problems: Kadcyla can cause inflammation or damage to cells in the liver that can stop the liver from functioning normally. Inflamed or injured liver cells may leak higher than normal amounts of certain substances (liver enzymes) into the bloodstream, resulting in elevated liver enzymes in blood tests. In most cases you will not have any symptoms. Some symptoms could be yellowing of your skin and whites of your eyes (jaundice). Your doctor will check your blood to test your liver function before and regularly during treatment.
Another rare abnormality that can occur in the liver is a condition known as nodular regenerative hyperplasia (NRH). This abnormality causes the structure of the liver to change and can change how the liver functions. Over time, this may lead to symptoms such as a bloated sensation or swelling of the abdomen due to fluid accumulation or bleeding from abnormal blood vessels in the gullet or rectum.
- Heart problems: Kadcyla can weaken the heart muscle. When the heart muscle is weak, patients may develop symptoms such as shortness of breath at rest or when sleeping, chest pain, swollen legs or arms, and a sensation of rapid or irregular heartbeats. Your doctor will check your heart function before and regularly during treatment. You should tell your doctor immediately if you notice any of the above symptoms.
- Infusion-related reactions or allergic reactions: Kadcyla can cause flushing, shivering fits, fever, trouble breathing, low blood pressure, rapid heartbeat, sudden swelling of your face, tongue, or trouble swallowing during the infusion or after the infusion on the first day of treatment. Your doctor or
nurse will check to see whether you are having any of these side effects. If you develop a reaction, they will slow down or stop the infusion and may give you treatment to counteract the side effects. The infusion may be continued after the symptoms improve.
- Bleeding problems: Kadcyla can lower the number of platelets in your blood. Platelets help your blood to clot so you might get unexpected bruising or bleeding (such as nose bleeds, bleeding from gums). Your doctor will check your blood regularly for decreased platelets. You should tell your doctor immediately if you notice any unexpected bruising or bleeding.
- Neurological problems: Kadcyla can damage nerves. You may experience tingling, pain, numbness, itching, crawling sensation, pins and needles in your
hands and feet. Your doctor will monitor you for signs and symptoms of neurological problems.
Tell your doctor or nurse straight away if you notice any of the side effects above.
Kadcyla is not recommended for anyone under the age of 18 years. This is because there is no information on how well it works in this age group.
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.
In particular, tell your doctor or pharmacist if you are taking:
- any medicines to thin your blood such as warfarin or decrease the ability to form blood clot such as aspirin
- medicines for fungal infections called ketoconazole, itraconazole or voriconazole
- antibiotics for infections called clarithromycin or telithromycin
- medicines for HIV called atazanavir, indinavir, nelfinavir, ritonavir or saquinavir.
- medicine for depression called nefazodone
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before you are given Kadcyla.
Kadcyla is not recommended if you are pregnant because this medicine may cause harm to the unborn baby.
- Tell your doctor before using Kadcyla if you are pregnant, think you may be pregnant or are planning to have a baby.
- Use effective contraception to avoid becoming pregnant while you are being treated with Kadcyla.. Talk to your doctor about the best contraception for you.
- You should continue to take your contraception for at least 7 months after your last dose of Kadcyla. Talk to your doctor before stopping your contraception.
- Male patients or their female partners should also use effective contraception.
- If you do become pregnant during treatment with Kadcyla, tell your doctor straight away.
You should not breast-feed during treatment with Kadcyla. Also you should not breast-feed for 7 months after your last infusion of Kadcyla. It is not known whether the ingredients in Kadcyla pass into breast-milk. Talk to your doctor about this.
It is not expected that Kadcyla will affect your ability to drive, cycle, use tools or machines. If you experience flushing, shivering fits, fever, trouble breathing, low blood pressure or a rapid heartbeat (infusion-related reaction), blurred vision, tiredness, headache, or dizziness, do not drive, cycle, use tools or machines until these reactions stop.
This medicine contains less than 1 mmol sodium (23 mg) per dose. It is essentially ‘sodium- free’.
Kadcyla will be given to you by a doctor or nurse in a hospital or clinic:
- It is given by a drip into a vein (intravenous infusion).
- You will be given one infusion every 3 weeks.
- You will be given 3.6 mg of Kadcyla for every kilogram of your body weight. Your doctor will calculate the correct dose for you.
- The first infusion will be given to you over 90 minutes. You will be observed by a doctor or nurse while it is being given and for at least 90 minutes following the initial dose, in case you have any side effects.
- If the first infusion is well tolerated, the infusion on your next visit may be given over 30 minutes. You will be observed by a doctor or nurse while it is being given and for at least 30 minutes following the dose, in case you have any side effects.
- The total number of infusions that you will be given depends on how you respond to the treatment.
- If you experience side effects, your doctor may decide to continue your treatment but lower your dose, delay the next dose or stop the treatment.
If you forget or miss your Kadcyla appointment, make another appointment as soon as possible. Do not wait until your next planned visit.
Do not stop treatment with this medicine without talking to your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common (may affect more than 1 in 10 people):
- Kadcyla may cause inflammation or damage to cells in the liver, resulting in elevated liver enzymes in blood tests. However, in most cases during Kadcyla treatment, liver enzyme levels are elevated mildly and temporarily, do not cause any symptoms, and do not affect liver function.
- Unexpected bruising and bleeding (such as nose bleeds).
- Tingling, pain, numbness, itching, crawling sensation, pins and needles in your hands and feet. These symptoms may indicate nerve damage.
Common (may affect up to 1 in 10 people):
- Flushing, shivering fits, fever, trouble breathing, low blood pressure or a rapid heartbeat during the infusion or up to 24 hours after the infusion – these are so-called infusion-related reactions.
- Heart problems can occur. Most patients will not have symptoms from the heart problems. If symptoms do occur, cough shortness of breath at rest or when sleeping flat, chest pain and swollen ankles or arms, a sensation of rapid or irregular heartbeats may be observed.
Uncommon (may affect up to 1 in 100 people):
- Inflammation of your lungs can cause breathing problems such as shortness of breath (either at rest or while performing any type of activity), coughing or coughing spells with a dry cough – these are signs of inflammation of your lung tissue.
- Your skin and whites of your eyes get yellow (jaundice) – these could be signs of severe liver damage.
- Allergic reactions can occur and most patients will have mild symptoms such as itching or tightness in the chest. In more severe cases, swelling of your face or tongue, trouble swallowing or difficulty breathing may occur.
Tell your doctor or nurse straight away if you notice any of the serious side effects above.
- decreased red blood cells (shown in a blood test)
- being sick (vomiting)
- dry mouth
- urinary tract infection
- stomach ache
- shortness of breath
- inflammation of the mouth
- chills or flu like symptoms
- decrease in your potassium levels (shown in a blood test)
- difficulty sleeping
- muscle or joint pain
- skin rashes
- feeling tired
- decreased white blood cells (shown in a blood test)
- dry eyes, watery eyes or blurred vision
- eye redness or infection
- swelling of legs and/or arms
- bleeding from the gums
- increase in blood pressure
- feeling dizzy
- taste disturbances
- difficulty in remembering
- hair loss
- hand-and-foot skin reaction (Palmar-plantar erythrodysaesthesia syndrome)
- nail disorder
- Another abnormality that can be caused by Kadcyla is a condition known as nodular regenerative hyperplasia of the liver. This abnormality causes the structure of the liver to change. Patients develop multiple nodules in the liver that can change how the liver functions. Over time, this may lead to symptoms such as a bloated sensation or swelling of the abdomen due to fluid accumulation or bleeding from abnormal blood vessels in the gullet or rectum.
- If the Kadcyla infusion solution leaks into the area around the infusion site you may develop tenderness or redness of your skin, or swelling at the infusion site.
If you get any of the side effects after your treatment with Kadcyla has stopped, talk to your doctor or nurse and tell them that you have been treated with Kadcyla.
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Yellow Card Scheme
Kadcyla will be stored by the health professionals at the hospital or clinic.
- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the outer carton after EXP. The expiry date refers to the last day of that month.
- Store in a refrigerator at (2°C - 8°C). Do not freeze.
- When prepared as a solution for infusion Kadcyla is stable for up to 24 hours at 2°C to 8°C, and must be discarded thereafter.
- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment.
- The active substance is trastuzumab emtansine.
- Each 100 mg single-use vial containing powder for concentrate for infusion solution designed to deliver 5 ml of 20 mg/ml of trastuzumab emtansine.
- Each 160 mg single-use vial containing powder for concentrate for infusion solution designed to deliver 8 ml of 20 mg/ml of trastuzumab emtansine.
- The other ingredients are succinic acid, sodium hydroxide (see section 2 under ‘Important information about some of the ingredients of Kadcyla’), sucrose, and polysorbate 20.
- Kadcyla is a white to off-white lyophilised powder for concentrate for solution for infusion supplied in glass vials.
- Kadcyla is available in packs containing 1 vial.
Roche Registration Limited
6 Falcon Way
Welwyn Garden City
Roche Pharma AG
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Roche Products Ltd.
Tel: +44 (0) 1707 366000
This leaflet was last revised in May 2017
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.